CIK 0001374690
- Non-accelerated filer
- Smaller reporting company
Larimar Therapeutics, Inc.
Sign in to watch- Ticker
- LRMR
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- EIN
- 203857670
- Phone
- +1 844-511-9056
- Business address
- THREE BALA PLAZA EAST. SUITE 506, BALA CYNWYD, PA, 19004
- Former names
- ZAFGEN, INC., ZAFGEN INC
- 4 Derivatives Options or other derivatives
- 4 Open-market buy Director bought 57,208 shares at $8.74 ($499,998)
- 4 Open-market buy Director bought 4,290,617 shares at $8.74 ($37,499,993)
- 4 Open-market buy Director bought 2,000 shares at $11.00 ($22,000)
- 4 Grant or award Chief Development Officer acquired 22,500 shares (grant or award)
- 4 Grant or award Chief Financial Officer acquired 31,250 shares (grant or award)
- 4 Grant or award Chief Medical Officer acquired 22,500 shares (grant or award)
- 4 Grant or award President and CEO acquired 66,125 shares (grant or award)
- 4 Open-market buy Chief Development Officer bought 5,000 shares at $3.73 ($18,662)
- 4 Derivatives Options or other derivatives
- 3 Insider Initial Statement of Ownership
- 4 Derivatives Options or other derivatives
- 3 Insider Initial Statement of Ownership
- 4 Open-market buy Chief Financial Officer bought 5,000 shares at $3.73 ($18,632)
- 4 Open-market buy President and CEO bought 5,000 shares at $3.71 ($18,525)
- 4 Open-market buy Director bought 2,750 shares at $3.73 ($10,258)
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
Page 3 of 14 · 272 filings